article thumbnail

STAT+: Make America Healthy Again is ringing through statehouses across the U.S.

STAT

From cancer warning labels to soda taxes , progressive states like California and New York have long led the way on legislation meant to improve public health. You’re reading The MAHA Diagnosis , a STAT series that examines the major elements of the Make America Healthy Again movement led by Robert F. Kennedy Jr.

Labelling 275
article thumbnail

Europe’s pharmaceutical packaging market to value over $35bn by 2028

European Pharmaceutical Review

Europe’s pharmaceutical packaging and labelling market is projected to reach $35.78 billion in 2028, according to a report by Arizton. billion in 2022, the pharmaceutical packaging and labelling market in Europe is expected to expand at a compound annual growth rate (CAGR) of 4.78 percent up to 2028. percent in 2022.

Packaging 118
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Fragile X syndrome market to quadruple to $111.9 million in US and Germany by 2030, forecasts GlobalData

Express Pharma

Zygel is expected to launch in Germany in 2028, whereas zatolmilast is not anticipated to launch in Germany during the forecast period. There are currently no approved therapies available for FXS; prescribed treatment consists exclusively of off-label drugs that target individual symptoms of the disease.

article thumbnail

Merck’s Welireg becomes first drug for rare VHL tumours in US

pharmaphorum

The drug is part of Merck’s efforts to expand its oncology portfolio and reduce its reliance on big-selling cancer immunotherapy Keytruda (pembrolizumab), which is patent protected in the US and Europe until 2028.

article thumbnail

CD19 CAR-T agents to boost blood cancer market

European Pharmaceutical Review

Breyanzi is approved for DLBCL, and a label expansion is anticipated for expansions into marginal zone lymphoma (MZL) and mantle cell lymphoma (MCL) in 2026 and 2028, respectively. This allows for a large total eligible patient population despite capturing less patient share relative to other CD19 CAR-T agents.

article thumbnail

Steriline to exhibit its Robotic Vial Filling Machine at ACHEMA 2024

Express Pharma

per cent per year until 2028 1. At the same time, the rising costs for filling, packaging and labelling medicines, added to the increased energy costs, could cause a fall in revenue for pharmaceutical manufacturers, which are under additional pressure because of fixed sales prices for drugs (i.e. in the EU).

Packaging 105
article thumbnail

High risk, high reward – the future of CAR-T therapy in CLL

Pharmaceutical Technology

According to GlobalData’s analyst consensus forecast, Yescarta is expected to reach peak sales of $1.8bn in 2028, and Kymriah is expected to reach sales of $686m in the same year. Autologous CAR-T agents are now becoming the standard of care for patients in the third line and later settings, providing lucrative returns for these agents.